The inflammation-microvascular axis in prognosis: Integrated FAI and AMR assessment for risk stratification after PCI in NSTEMI patients.

Isolated T-Wave Inversion in Lead aVL: A Diagnostic Blind Spot in Emergency Department Chest Pain Evaluation.

Isolated Transcatheter and Surgical Aortic Valve Replacement in the Evolut Low-Risk Trial: 5-Year Comparative Outcomes.

Long-term prognostic value of residual lipid burden in acute myocardial infarction.

Design and rationale of the clinical trial to obtain the highest efficacy of dual antiplatelet therapy after carotid artery stenting in high bleeding risk patients (CHET): A multicenter, randomized, open-label, superiority trial.

Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Lung Transplant Candidates: Striking a Surgical Balance

The impact of the BCIS CHIP score on the prognosis of ischemic acute heart failure.

Percutaneous coronary intervention (PCI) for ostial right coronary artery (RCA) lesions remains challenging and is associated with higher rates of restenosis and target lesion revascularization, even in the contemporary drug-eluting stent era. These unfavorable outcomes are largely attributable to the unique anatomical and histological characteristics of the aorto-ostial junction, including severe calcification, limited vessel compliance, and hinge motion. Intravascular ultrasound (IVUS) studies have identified distinct morphological patterns of ostial RCA lesions, including isolated ostial lesions, diffuse atherosclerotic disease without calcified nodules, and lesions characterized by calcified nodules, which are associated with poorer clinical outcomes. Optimal management of ostial RCA lesions requires careful lesion assessment and tailored therapeutic strategies. For de novo lesions, adequate lesion preparation using high-pressure/scoring balloon dilation, rotational atherectomy (RA), or intravascular lithotripsy is essential to achieve optimal stent expansion. Precise ostial stent placement and intravascular imaging-guided optimization are critical procedural components, and drug-coated balloon (DCB) therapy may be considered in selected cases with a high risk of restenosis. In-stent restenosis (ISR) of the ostial RCA is frequently driven by mechanical factors such as stent underexpansion or fracture. DCBs are the preferred first-line treatment for ISR, while additional lesion modification using high-pressure balloons, RA may be required in cases with significant mechanical constraints. This review summarizes current evidence on the morphology, mechanisms, and contemporary treatment strategies for ostial RCA lesions, with a particular focus on intravascular imaging-guided intervention and practical considerations in clinical practice.

A novel theoretical model and experimental validation of backup force in percutaneous coronary intervention.

Modified guide-extension proximal locking method using dual guiding catheters (GP-Lock-DG) in percutaneous coronary intervention.

Operator radiation exposure comparing left-radial artery and right-radial artery approaches: A systematic review and meta-analysis.

Cost-Utility and Budget Impact Analysis of Pharmacogenetic-Guided Antiplatelet Therapy for Acute Coronary Syndrome in Thailand.

Rate of In-Stent Restenosis in Percutaneous Coronary Intervention for Cardiac Allograft Vasculopathy

Fractional flow reserve-guided percutaneous coronary intervention for transcatheter aortic valve implantation: a FAITAVI accompli for better outcomes?

Dynamic Coronary Roadmap (DCR) is a novel software providing a motion-compensated, real-time overlay of coronary arteries to assist PCI device navigation with a single contrast injection. This meta-analysis evaluated the effectiveness and safety of DCR. We searched PubMed, Scopus, Web of Science, Cochrane Library, and Embase from inception to May 5, 2024. Outcomes were pooled as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CI) using random-effects models. PROSPERO registration: CRD42024553689. Eight studies (two RCTs, six observational; 1,512 patients) were included. DCR-guided PCI significantly reduced contrast media volume (MD = - 45.82mL, 95% CI - 68.33 to - 23.30; P < 0.001; I2 = 97%), air kerma (MD = - 283.09mGy, 95% CI - 474.47 to - 91.70; P = 0.004; I2 = 99%), dose area product (MD = - 6.85Gy/cm2, 95% CI - 10.48 to - 3.22; P = 0.0002; I2 = 82%), radiation duration (MD = - 2.79min, 95% CI - 4.59 to - 0.98; P = 0.002; I2 = 94%), and procedural duration (MD = - 3.51min, 95% CI - 6.69 to - 0.32; P = 0.03; I2 = 0%). No significant differences were found in procedural success (RR = 1.00; 95% CI 0.99-1.01; I2 = 0%) or acute kidney injury incidence (RR = 0.40; 95% CI 0.15-1.08; I2 = 0%). Risk of bias was mixed for RCTs (low to high risk across domains) and moderate to high for observational studies, with most scoring ≥ 7 on the Newcastle-Ottawa Scale. DCR-guided PCI was associated with reductions in contrast use and radiation metrics without compromising procedural success; however, the overall certainty of evidence is low due to study design limitations, risk of bias, and substantial heterogeneity, warranting cautious interpretation.

Immediate Aspirin Discontinuation Following Percutaneous Coronary Intervention for Acute Coronary Syndromes.

The impact of pulmonary hypertension and comorbidities on in-hospital mortality in hypertrophic obstructive cardiomyopathy: A nationwide analysis from 2016 to 2021.

Intelligent tutoring-assisted training enhances the skill development of percutaneous coronary intervention

Comparative validation of risk scores for in-hospital complications following chronic total occlusion percutaneous coronary intervention.

Longer total stent length (TSL) increases the risk of target lesion failure (TLF) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention with second-generation drug-eluting stents (DES). We aimed to assess the long-term impact of TSL on patient- and stent-related outcomes in STEMI patients treated with different newer-generation DES designs. We performed a post hoc subgroup analysis of the BIOSTEMI Extended Survival randomized trial (NCT05484310). Patients undergoing primary percutaneous coronary intervention for STEMI were randomized to ultrathin-strut biodegradable-polymer sirolimus-eluting stents (BP-SES) or thin-strut durable-polymer everolimus-eluting stents (DP-EES) and categorized according to TSL implanted at the culprit site (≤40 vs >40 mm). The device-oriented composite endpoint (TLF) was the composite of cardiac death, target-vessel myocardial reinfarction, or clinically indicated target lesion revascularization, and the patient-oriented composite endpoint was the composite of all-cause death, any myocardial reinfarction, any revascularization, or any stroke, at 5 years. A total of 1,686 STEMI patients were included (mean age, 62.4 years; female, 23%; mean TSL, 33.8 mm), of whom 423 (25%) were treated with TSL >40 mm. At 5 years, TSL >40 mm was associated with a significantly higher risk of patient-oriented composite endpoint compared with TSL ≤40 mm (31.7% vs 27.4%; hazard ratio [HR], 1.30; 95% confidence interval [CI], 1.03-1.64; P = .029), whereas no difference was observed in TLF. However, there was a significant interaction between DES type and TSL for TLF at 5 years. Among patients with TSL >40 mm, BP-SES were associated with a lower risk of TLF compared with DP-EES (7.3% vs 17.1%; HR, 0.39; 95% CI, 0.21-0.74; P = .004; P for interaction = .032), a difference primarily driven by a lower rate of target vessel myocardial reinfarction. No significant differences between BP-SES and DP-EES were observed in patients with TSL ≤40 mm. After adjustment for multivessel treatment, increasing TSL with DP-EES, but not BP-SES, was independently associated with a higher risk of TLF (adjusted HR per 5-mm increase, 1.07; 95% CI, 1.02-1.11; P = .003). In STEMI patients treated with contemporary DES, TSL >40 mm was associated with an increased risk of patient-oriented, but not device-related, adverse outcomes at 5 years. Among patients requiring TSL >40 mm, ultrathin-strut BP-SES significantly reduced the risk of TLF compared with DP-EES, whereas no between-DES differences were observed in patients treated with TSL ≤40 mm. The BIOSTEMI ES trial is registered at ClinicalTrials.gov (NCT05484310).